摘要
目的:探究扶正口服液联合mFOLFOX6(奥沙利铂+亚叶酸钙+氟尿嘧啶)化疗在结直肠癌患者中的临床应用效果。方法:随机选取江阴市中医院2020年1月—2022年12月间收治的80例结直肠癌患者纳入本次研究,依据电脑随机数字法将其分为对照组和研究组,每组40例。对照组行mFOLFOX6化疗方案,研究组行mFOLFOX6化疗方案增加扶正口服液治疗。对两组疗效、肿瘤标志物水平、炎症水平、用药安全性及生存质量进行对比分析。结果:研究组总缓解率(ORR)和疾病控制率(DCR)均高于对照组(P<0.05)。治疗前,两组肿瘤标志物及免疫水平差异无统计学意义(P>0.05)。治疗后,两组糖类抗原125(CA125)、CA19-9、癌胚抗原(CEA)水平均低于治疗前(P<0.05),研究组明显低于对照组(P<0.01);治疗后,两组C反应蛋白(CRP)、白细胞介素-6(IL-6)水平均低于治疗前(P<0.05),研究组低于对照组(P<0.01)。研究组不良反应明显少于对照组(P<0.05)。治疗前,两组KPS评分差异无统计学意义(P>0.05)。治疗后,两组KPS评分均高于治疗前(P<0.05),研究组高于对照组(P<0.01)。结论:对结直肠癌患者应用扶正口服液联合mFOLFOX6化疗方案进行治疗,可明显提升疗效,改善肿瘤标志物及炎症水平,同时能有效减少化疗所致不良反应,从而有效改善患者生存质量。
Objective:To explore the clinical effects of Fuzheng oral liquid combined with mFOLFOX6(Oxaliplatin+leucovorin+fluorouracil)chemotherapy in colorectal cancer patients.Method:A total of eighty colorectal cancer patients who were admitted to Jiangyin Hospital of Traditional Chinese Medicine between January 2020 and December 2022 were randomly selected for inclusion in this study.They were divided into a control group(n=40)and a study group(n=40)according to the computer generated random number.The control group received mFOLFOX6 chemotherapy,and the study group received mFOLFOX6 chemotherapy plus Fuzheng oral liquid.The efficacy,tumor marker levels,inflammation levels,medication safety,and quality of life were compared between the two groups.Result:The overall remission rate(ORR)and disease control rate(DCR)of the study group were significantly higher than those of the control group(P<0.05).Before treatment,there were no statistically significant differences in tumor markers and immune levels between the two groups(P>0.05).After treatment,the levels of carbohydrate antigen 125(CA125),CA19-9,and carcinoembryonic antigen(CEA)were lower than before treatment in both groups(P<0.05),and they were significantly lower in the study group than in the control group(P<0.05).After treatment,the levels of C-reactive protein(CRP)and interleukin-6(IL-6)were significantly lower in both groups than before treatment(P<0.05),and they were significantly lower in the study group than in the control group(P<0.05).Adverse effects were significantly lower in the study group than in the control group(P<0.05).Before treatment,KPS scores were not statistically different between the two groups(P>0.05).After treatment,KPS scores in both groups were significantly higher than before treatment(P<0.05),and it was significantly higher in the study group than in the control group(P<0.05).Conclusion:Treatment with Fuzheng oral liquid combined with mFOLFOX6 chemotherapy in patients with colorectal cancer can significantly improve the efficacy and the levels of tumor markers and inflammation.At the same time,it can effectively reduce the adverse effects caused by chemotherapy,thus effectively improving the quality of patient lives.
作者
张乐裕
邢益阳
ZHANG Leyu;XING Yiyang(Department of Oncology,Jiangyin Hospital of Traditional Chinese Medicine,Wuxi 214400,China)
出处
《中医药学报》
CAS
2024年第3期61-65,共5页
Acta Chinese Medicine and Pharmacology
基金
江苏省自然科学基金资助课题(HBK2011078)。
